The following is a transcript of a telephone interview conducted for the IPA(International Pompe Association) by Kevin O’Donnell of the

Excerpt from Pharming Press Release—March 30, 2001 LEIDEN, the Netherlands, March 30, 2001 – Pharming Group N.V. announced the start

Excerpt From Press Release-March 20, 2001 CAMBRIDGE, MA and LEIDEN,the Netherlands—Genzyme General (Nasdaq: GENZ), a division of Genzyme Corp., and

The following is a transcript of a telephone interview conducted for the IPA(International Pompe Association) by Kevin O’Donnell of the

Excerpt From Press Release—October 5, 2000 Genzyme General and Pharming Group N.V., announced today that results from the first two

Chen focused on the phase I/II trials underway at Duke with 3 IIa infants. Average age at diagnosis is 5

Genzyme Corporation and it’s development partner, Pharming N.V., are committed to providing an effective and practical therapy for Pompe disease

The Lancet—July 29, 2000 Recombinant human alpha-glucosidase from rabbit milk in Pompe patients Lancet 2000; 356: 397-398 Hannerieke Van den

Genzyme and Pharming to Fund Commercialization Cambridge, Mass., USA, Durham, N.C., USA, and Leiden, the Netherlands, April 19, 2000 –

Pharming’s first Phase II clinical trialA research study that tests new treatments or approaches in people. More for Pompe’s disease finalised, showing survival, skeletal muscleMuscles that control movement and are commonly affected in Pompe disease. More regeneration and overall improvement of heart